IL164809A0 - Novel phosphonic acid basdrugs of pmea and its analogues - Google Patents

Novel phosphonic acid basdrugs of pmea and its analogues

Info

Publication number
IL164809A0
IL164809A0 IL16480903A IL16480903A IL164809A0 IL 164809 A0 IL164809 A0 IL 164809A0 IL 16480903 A IL16480903 A IL 16480903A IL 16480903 A IL16480903 A IL 16480903A IL 164809 A0 IL164809 A0 IL 164809A0
Authority
IL
Israel
Prior art keywords
basdrugs
pmea
analogues
phosphonic acid
novel phosphonic
Prior art date
Application number
IL16480903A
Other languages
English (en)
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of IL164809A0 publication Critical patent/IL164809A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16480903A 2002-05-13 2003-05-12 Novel phosphonic acid basdrugs of pmea and its analogues IL164809A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38054502P 2002-05-13 2002-05-13
PCT/US2003/014821 WO2004037161A2 (en) 2002-05-13 2003-05-12 Cyclic prodrugs of pmea one of its analogues

Publications (1)

Publication Number Publication Date
IL164809A0 true IL164809A0 (en) 2005-12-18

Family

ID=32176361

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16480903A IL164809A0 (en) 2002-05-13 2003-05-12 Novel phosphonic acid basdrugs of pmea and its analogues
IL164809A IL164809A (en) 2002-05-13 2004-10-25 History [1. 2.3] Dioxapospinan 2-Oxide as pharmaceuticals and pharmaceuticals containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL164809A IL164809A (en) 2002-05-13 2004-10-25 History [1. 2.3] Dioxapospinan 2-Oxide as pharmaceuticals and pharmaceuticals containing them

Country Status (9)

Country Link
US (1) US7214668B2 (OSRAM)
EP (2) EP1532157A4 (OSRAM)
JP (1) JP4476811B2 (OSRAM)
AU (1) AU2003299492B2 (OSRAM)
CA (1) CA2485702C (OSRAM)
IL (2) IL164809A0 (OSRAM)
NZ (1) NZ536328A (OSRAM)
TW (1) TWI347325B (OSRAM)
WO (1) WO2004037161A2 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
EP1504014B1 (en) * 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
CA2503730C (en) * 2002-10-31 2011-10-18 Metabasis Therapeutics, Inc. Cytarabine monophosphate prodrugs
WO2005072748A1 (en) * 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2005254940A1 (en) 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
WO2006055525A2 (en) * 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2007013085A1 (en) * 2005-07-26 2007-02-01 Hetero Drugs Limited Novel process for acyclic phosphonate nucleotide analogs
US20070042501A1 (en) * 2005-08-20 2007-02-22 Institute Of Nuclear Energy Research A novel technology for the purity assay of TRODAT-1 raw material
PL2020996T3 (pl) * 2006-05-16 2012-04-30 Gilead Sciences Inc Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego
CN101371841A (zh) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 结晶型恩替卡韦制剂及其制备方法和应用
JP2009196959A (ja) * 2008-02-25 2009-09-03 Yamaguchi Univ がん治療用医薬組成物
CN101475594B (zh) * 2009-02-06 2012-05-30 廖国超 肝靶向抗病毒前体药物环状磷酸酯及其应用
CN101659676B (zh) * 2009-09-07 2012-06-20 徐奎 一种硫代阿德福韦、替诺福韦肝靶向酯前体药物
US8940313B2 (en) 2010-04-23 2015-01-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
WO2012062835A1 (en) * 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Novel pharmaceutical compositions
FI2648701T3 (fi) 2010-12-10 2023-06-12 Sigmapharm Laboratories Llc Hyvin stabiileja adefovirdipivoksiilin koostumuksia
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN103333209B (zh) * 2013-07-05 2015-09-30 西安新通药物研究有限公司 替诺福韦前药(hts)新晶体
CN104710477A (zh) * 2013-12-16 2015-06-17 安徽贝克联合制药有限公司 替诺福韦环膦酸酯化合物及其药学上可接受的盐和其制备方法及应用
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017220028A1 (zh) 2016-06-24 2017-12-28 浙江柏拉阿图医药科技有限公司 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
CN107540710B (zh) * 2016-06-24 2020-10-16 浙江柏拉阿图医药科技有限公司 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN108863797B (zh) * 2018-07-02 2021-01-15 吉首大学 一类3-(取代/非取代苯基)-3-羟基丙酰氧肟酸的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR75178E (OSRAM) * 1956-12-20 1961-09-08
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
DE68924456T2 (de) 1988-08-02 1996-05-30 Nissan Chemical Ind Ltd Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel.
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CS387190A3 (en) * 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5157027A (en) * 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
EP0632048B1 (en) * 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
DE4445829A1 (de) 1994-12-22 1996-06-27 Leybold Ag Gegenstrom-Schnüffellecksucher
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
DK0871454T3 (da) 1995-07-17 2004-03-22 Cephalon Inc Phosphorholdige inhibitorer af cystein- og serinprotease
US5962440A (en) * 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ES2210728T3 (es) 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
KR100700089B1 (ko) 1997-07-25 2007-03-28 길리애드 사이언시즈, 인코포레이티드 뉴클레오티드 동족체의 제조에 사용되는 중간체의 제조방법
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
HK1042496B (zh) * 1998-09-09 2006-01-27 症变治疗公司 新的果糖1，6-二磷酸酶的杂芳族抑制剂
CA2354053A1 (en) 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
JP5063837B2 (ja) 1999-03-05 2012-10-31 リガンド・ファーマシューティカルズ・インコーポレイテッド 新規リン含有プロドラッグ
US6752981B1 (en) * 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
EP1504014B1 (en) * 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
CA2503730C (en) * 2002-10-31 2011-10-18 Metabasis Therapeutics, Inc. Cytarabine monophosphate prodrugs
PL212403B1 (pl) * 2003-12-30 2012-09-28 Gilead Sciences Pochodna fosfonianowa, kompozycja farmaceutyczna zawierajaca ten zwiazek oraz jego zastosowanie w leczeniu guzów
AU2005254940A1 (en) * 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters

Also Published As

Publication number Publication date
CA2485702A1 (en) 2004-05-06
WO2004037161A2 (en) 2004-05-06
US7214668B2 (en) 2007-05-08
IL164809A (en) 2012-08-30
TW200426152A (en) 2004-12-01
JP4476811B2 (ja) 2010-06-09
CA2485702C (en) 2011-07-19
WO2004037161A3 (en) 2005-03-31
AU2003299492A1 (en) 2004-05-13
EP2223927A3 (en) 2010-09-15
EP1532157A2 (en) 2005-05-25
NZ536328A (en) 2007-11-30
TWI347325B (en) 2011-08-21
EP1532157A4 (en) 2009-02-25
EP2223927B1 (en) 2014-10-15
AU2003299492B2 (en) 2010-06-10
JP2006511490A (ja) 2006-04-06
EP2223927A2 (en) 2010-09-01
US20030229225A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
IL164809A0 (en) Novel phosphonic acid basdrugs of pmea and its analogues
ZA200407950B (en) Bisphosphonic acid for the treatment and prevention of osteoporosis
PL372814A1 (en) Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
PL371526A1 (en) Phosphorus-containing compounds and uses thereof
GB0112699D0 (en) Process for the preparation of prostglandins and analogues thereof
PL375784A1 (en) Use of erythopoietin
AU2003286176A8 (en) Fungicidal compositions containing at least one salt of phosphorous acid and at least a second fungicidal component
EP1487776A4 (en) ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
AU2003287063A8 (en) Hemostatic and acid etch compositions containing sucralose
GB2413556B (en) A new crystal form of adefovir dipivoxil and its composition
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
GB0230240D0 (en) Removal of an acid
PL366980A1 (en) Hydroxyeicosenoic acid analogs
HK1074049A (en) Novel phosphonic acid based prodrugs of pmea and its analogues
AU2003298725A8 (en) Preparation of metallotexaphyrins
AU2003289782A1 (en) Valproic acid analogues and pharmaceutical compositions thereof
AU2003266264A8 (en) Diphenyl ether and n-(phosphonomethyl)glycine herbicidal compositions and methods of use
AU2003280271A8 (en) Phosphinic acid analogs of glutamate
AU2003276877A8 (en) Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
PL361197A1 (en) New analogues of panthotenic acid and method for manufacture of new analogues of panthotenic acid
AU2003267733A1 (en) Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid
PL373284A1 (en) Analogues of vitamin d
SI1537065T1 (sl) Analogi D vitamina
TW560715U (en) Improved structure of CPU socket
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides